Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Authors' conclusion
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists.
Study context
- Population
- Adults with obesity without DMrandomized 3:3:3:4
- Participants
- 3,127 adults
- Comparison
- Once-daily oral orforglipron 6 mg, 12 mg or 36 mg vs placebo, adjunct to healthy diet and physical activity
- Primary endpoint
- Percent change in body weight from baseline
- Follow-up
- Week 72
Methodological detailsphase 3, multinational, double-blind, placebo-controlled
- Phase 3
- Multinational
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Orforglipron 6 mg
−7.5
mean · 95% CI −8.2–-6.8 · %
Orforglipron 12 mg
−8.4
mean · 95% CI −9.1–-7.7 · %
Orforglipron 36 mg
−11.2
mean · 95% CI −12.0–-10.4 · %
Placebo
−2.1
mean · 95% CI −2.8–-1.4 · %
Orforglipron 6 mg vs Placebo: P < 0.001 for all comparisons with placebo · Orforglipron 12 mg vs Placebo: P < 0.001 for all comparisons with placebo · Orforglipron 36 mg vs Placebo: P < 0.001 for all comparisons with placebo
Further findings
| Outcome | Orforglipron 36 mg | Placebo |
|---|---|---|
| Body weight reduction ≥10% · week 72 | 54.6% | 12.9% |
| Body weight reduction ≥15% · week 72 | 36.0% | 5.9% |
| Body weight reduction ≥20% · week 72 | 18.4% | 2.8% |
Cardiometabolic risk factors
- Waist circumference, systolic blood pressure, TG and non-HDL cholesterol significantly improved with orforglipron vs placebo
Safety
- Adverse events leading to treatment discontinuation — Placebo
- 2.7%
- Adverse events leading to treatment discontinuation — Discontinuation due to adverse events, orforglipron groups
- 5.3 to 10.3%
Adverse events leading to treatment discontinuation
- Most common adverse events with orforglipron were gastrointestinal, mostly mild to moderate
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →